Recurrence of endometriosis; risk factors, mechanisms and biomarkers; review of the literature

review OA: diamond CC0 ⤵ 61 in-corpus citations
AI-generated summary by claude@2026-06, 2026-06-08

This literature review examines endometriosis recurrence risk factors, mechanisms, and biomarkers, noting wide variability in recurrence rates and the ongoing debate about predictive factors and treatment success.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-10

This literature review examines recurrence of endometriosis after treatment, summarizing how frequently it occurs across studies (overall reported rates of 6–67% depending on criteria) and noting that the factors most predictive of recurrence remain controversial. It discusses proposed mechanisms for recurrent lesions, including regrowth from residual visible disease or emergence from de novo cells, and frames postoperative medical therapy as aiming to suppress ovarian activity to induce atrophy with success tied to both resorption of residual lesions and eradication of microscopic implants. The review also addresses the rationale for identifying risk factors to define at-risk subgroups and for developing biomarkers to support targeted therapy. This paper is centrally about endometriosis — it reviews recurrence risk factors, mechanisms, and candidate biomarkers.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Endometriosis has a wide clinical spectrum and induces a chronic inflammatory process. The incidence of endometriosis in women with dysmenorrhoea is up to 40-60%, whereas in women with subfertility is up to 20-30%. Recurrence of endometriosis varies greatly among different studies. The overall recurrence rates range between 6 to 67% according to the criteria that are taken into consideration. Which of the various reasons is more predictive for recurrence is still unclear and controversial. The main aim of post-operative medical treatment is suppressing ovarian activity leading to atrophy of endometriotic lesions. The success of treatment depends on the resorption of all residual visible lesions and the eradication of microscopic implants. The recurrent lesions might originate from residual lesions or from de novo cells. Determining risk factors for recurrence may allow the identification of subgroups at risk for disease control. Potential biomarkers for recurrence could also maintain targeted therapy.

My notes (saved in your browser only)

Condition tags

endometriosisdysmenorrhea

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (68)

Cited by (50)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:19:12.052662+00:00
License: CC0 · commercial use OK